Stokovic, Nikola
Ivanjko, Natalia
Rumenovic, Viktorija
Breski, Anita
Sampath, Kuber T.
Peric, Mihaela
Pecina, Marko
Vukicevic, Slobodan http://orcid.org/0000-0003-4076-0285
Funding for this research was provided by:
FP7 Health (HEALTH-F4-2011-279239)
H2020 Health (779340)
European Regional Development Fund (KK.01.1.1.01.0008)
Article History
Received: 3 August 2022
Accepted: 8 August 2022
First Online: 22 August 2022
Declarations
:
: Study has received ethics approval from the Ethics Committee at School of Medicine, University of Zagreb and the Croatian National Ethics Committee (EP 191/2019 and EP 296/2020).Animal care complied with the SOPs of the Animal Facility and the European conventions for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123). The ethical principles of the study ensured compliance with European Directive 010/63/E, the Law on Amendments to Animal Protection Act (Official Gazette 37/13, the Animal Protection Act (Official Gazette 102/17), the Ordinance on the Protection of Animals used for Scientific Purposes (Official Gazette 55/13), and FELASA recommendations.
: Not applicable.
: Not applicable.
: Slobodan Vukicevic is a founder of Genera Research and a coordinator of the EU HORIZON 2020 grant OSTEOproSPINE, funding clinical studies for new bone repair drugs (patent WO2019076484A1).